PharmTech Drug Digest 11.20
|Articles|July 8, 2010

Regulatory Roundup: Ethics Group Calls on FTC to Investigate Drug Pricing

Ethics Group Calls on FTC to Investigate Drug Pricing

The Citizens for Responsibility and Ethics in Washington, a nonprofit organization dedicated to promoting ethics and accountability, sent a letter to the Federal Trade Commission (FTC) on July 6, 2010, asking for the commission to investigate drug companies “that offer significant discounts to doctors for providing patients with only that company’s vaccines.” The organization claims that Sanofi Pasteur and Merck “offer significant price discounts” if healthcare groups agree to buy their vaccines solely from one manufacturer. The organization states that this practice prevents doctors from using alternative vaccines, even when they may better meet patient needs.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.